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Abstract: Vertical transmission from an infected cow to its fetus accounts for the vast 
majority of new Neospora caninum infections in cattle. A vaccine composed of a chimeric 
antigen named recNcMIC3-1-R, based on predicted immunogenic domains of the two 
microneme proteins NcMIC1 and NcMIC3, the rhoptry protein NcROP2, and emulsified in 
saponin adjuvants, significantly reduced the cerebral infection in non-pregnant BALB/c 
mice. Protection was associated with a mixed Th1/Th2-type cytokine response. However, 
the same vaccine formulation elicited a Th2-type immune response in pregnant mice and 
did not prevent vertical transmission or disease, neither in dams nor in offspring mice. In 
this study, an alternative vaccine formulation containing recNcMIC3-1-R emulsified in 
Freund’s incomplete adjuvant, a stimulator of the cellular immunity, was investigated. No 
protection against vertical transmission and cerebral infection in the pregnant mice and a 
very limited protective effect in the non-pregnant mice were observed. The vaccine 
induced a Th1-type immune response characterized by high IgG2a titres and strong IFN-γ 
expression, which appeared detrimental to pregnancy.  
Keywords: Neospora caninum; vaccination; recombinant antigen; pregnancy; vertical 
transmission; cytokines; mouse model; abortion 
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1. Introduction 
Neospora caninum is an intracellular apicomplexan parasite, which is reported as a major cause of 
bovine abortion worldwide, and thus, neosporosis represents an important veterinary disease of high 
economic significance [1–3]. Vaccination against bovine neosporosis is a rational approach that 
appears to be the most cost-effective method for the control of the disease [4,5]. In order to confer 
optimal protection against neosporosis, a vaccine should be able to prevent both, the horizontal 
transmission from contaminated food or water and vertical transmission from an infected cow to its 
fetus [6,7]. Different strategies for the development of such a vaccine have been investigated [8–11]. 
The only commercialized vaccine, based on tachyzoite extract [12] did not achieve the required 
protection against vertical transmission [13] and was recently withdrawn from the market. However, 
more recent studies employing live vaccines showed promising results in cattle [14] and mice (reviewed 
in [10,15]). Our investigations focus on the use of recombinant proteins for vaccination against 
experimental challenge in the mouse model. Indeed, the mouse model provides valuable  
proof-of-concept data [16–19]. Studies employing different recombinant protein vaccine candidates 
have shown promising results in terms of limiting the parasite load and reducing the effects of the 
disease (reviewed in [15]). For instance, vaccination of mice with recNcMIC1 [20], recNcMIC3 [21] and 
recNcROP2 [22] conferred protection against cerebral infection and against vertical transmission when 
combined in a single dose vaccine [23]. Vaccination with a recombinant chimeric antigen composed of 
putative immunogenic domains of the three proteins (recNcMIC3-1-R) predicted in silico and 
emulsified in saponin adjuvants conferred a high level of protection against cerebral infection in  
non-pregnant mice [24], but did not prevent vertical transmission, nor cerebral infection in pregnant 
mice [25]. Comparison of antibody responses and cytokine data in pregnant and non-pregnant mouse 
models showed that a mixed Th1-/Th2-type immune response was associated with the protection 
observed in the non-pregnant mouse model, but a Th2-biased immune response was observed in the 
pregnant mice [24]. The use of saponin, a stimulator of humoral immunity, in the pregnant mouse 
model was thus thought to be detrimental to the Th1/Th2 balance that is obviously required for 
protection [25]. Thus, the use of an adjuvant that stimulates the cellular immunity, in order to 
counterbalance the inherent Th2-type biased immune response observed in the pregnant mice, may 
lead to protection. It was shown earlier that immunization of mice with antigens emulsified in 
complete or incomplete Freund’s adjuvant induced a Th1-type immune response by stimulating IFN-γ 
production [26,27]. In this paper, we report on the use of recNcMIC3-1-R emulsified in Freund’s 
incomplete adjuvant (FIA) for vaccination in the pregnant mouse model. 
2. Results and Discussion 
2.1. Cerebral Infection in Pregnant Mice 
None of the formulations used produced visible lesions at the inoculation site or detectable adverse 
effects. All mice from the non-infected group survived without any clinical sign until the end of the 
experiment, and they tested all negative for N. caninum DNA in the brain (Table 1). All pregnant mice 
from the infected groups presented clinical signs of neosporosis and had to be killed before the end of 
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the experiment, except for three out of eight mice in the group vaccinated with N. caninum crude 
extract (Table 1).  
Table 1. Neosporosis in experimentally infected mice. 
Experimental 
groups 
No. of 
mice 
No. of sick mice 
(%)a 
Mortality (%)b 
Nc DNA in brain 
(%)c 
Mean parasite load (±SD)d 
P NP P NP P NP P NP P NP 
Non-infected control 9 11 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (±0) 0 (±0) 
FIA control 13 7 13 (100) 7 (100) 13 (100) 5 (71.4) 13 (100) 7 (100) 1446 (±184) 1054 (±204) 
MIC3-1-R in FIA 8 12 8 (100) 9 (75) 8 (100) 7 (58.3) 8 (100) 12 (100) 1342 (±187) 851 (±364) 
Crude extract in FIA 8 11 8 (100) 8 (72.7) 5 (62.5) 6 (54.5) 8 (100) 11 (100) 1179 (±400) 748 (±443) 
a Number of mice presenting at least one clinical sign of neosporosis (percentage); b Number of mice killed 
upon severe disease signs (percentage); c Number of dams tested positive for N; caninum DNA in the brain 
(percentage); d Mean parasite load per 80ng DNA in the positive mice (standard deviation); P = pregnant 
mice; NP = non-pregnant mice. 
The survival of the mice in the crude extract group was slightly higher than in the other infected 
groups, and the survival probability was significantly increased compared to each of the other infected 
groups (P < 0.01, Cox regression analysis) (Figure 1A). However, all mice from the infected groups 
tested positive for N. caninum DNA in the brain (Table 1, Figure 1B), and no significant difference 
between the parasite loads was observed between the groups. After delivery, the weight of the  
non-infected mice was significantly higher than the weight of all infected mice until the end of the 
experiment (P < 0.01, Mann-Whitney U-test) (Figure 1C). Significant differences between the crude 
extract group and the other infected groups were only observed at particular time points during the 
experiment (data not shown). 
Figure 1. Effects of vaccination in pregnant mice. (A) Kaplan-Meier survival curves of 
mice; n indicates the number of mice per group; * indicates a significant difference compared 
to the FIA group (P < 0.01). (B) Cerebral parasite burden assessed by quantitative  
real-time PCR. The y-axis represents the number of parasites detected in 20 ng of DNA 
extracted from brain tissue. No significant difference between the infected groups was 
observed. (C) Mean weight of the surviving mice per group. 
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Figure 1. Cont. 
 
2.2. Cerebral Infection in Non-pregnant Mice 
Non-pregnant mice presenting clinical signs of neosporosis were observed in all infected groups. 
However, a minority of mice from each vaccinated group did not present clinical signs and almost half 
of the mice from each of these groups survived until the end of the experiment (Table 1, Figure 2A). 
The mortality rate of the mice in the two vaccinated groups was lower than in the FIA group (Table 1), 
although the survival curves were not statistically different from the adjuvant control group (Log-rank 
test) (Figure 2A). All mice from the infected groups were nonetheless positive for N. caninum DNA in 
the brain (Table 1), but the parasite load in each infected group was significantly lower than in the 
respective group in the pregnant mice (P < 0.01 for the FIA and MIC3-1-R groups; P < 0.05 for the 
crude extract group, Mann-Whitney U-test) (Figure 2B). However, no significant difference between 
the vaccinated groups and the adjuvant control group was observed. No significant difference between 
the mean weights of the survivors at the end of the experiment was observed (Figure 2C).  
Figure 2. Effect of vaccination in non-pregnant mice. (A) Kaplan-Meier survival curves of 
mice; n indicates the number of mice per group; * indicates a significant difference 
compared to the FIA group (P < 0.01). (B) Cerebral parasite burden assessed by 
quantitative real-time PCR. The y-axis represents the number of parasites detected in 20 ng 
of DNA extracted from brain tissue. No significant difference between the infected groups 
was observed. (C) Mean weight of the surviving mice per group.  
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Figure 2. Cont. 
 
2.3. Vertical Transmission 
No significant difference in the fertility rate was observed between the groups. However, the litter 
size in the non-infected group was significantly bigger than in all infected groups (P < 0.05,  
Mann-Whitney U-test), and the neonatal mortality was significantly lower in the non-infected group  
(P < 0.05, Mann-Whitney U-test) (Table 2).  
Table 2. Effects of N. caninum infection of pregnant mice on offspring survival in the 
different experimental groups.  
Experimental groups 
Fertility 
(%)a 
No. of 
pupsb 
Average litter 
size (+/- SD) 
Neonatal 
mortality (%)c 
Postnatal 
mortality (%)d 
Non-infected control 9/20 (45) 60 6.7 (1.7) 1 (1.7) 0/59 (0) 
FIA control 13/20 (65) 64 4.9 (1.6) 13 (20.3) 51/51 (100) 
MIC3-1-R in FIA 8/20 (40) 37 4.6 (1.4) 10 (27.0) 27/27 (100) 
Crude extract in FIA 8/19 (42.1) 37 4.6 (1.7) 7 (18.9) 28/30 (93.3) 
a Number of pregnant mice / number of mice in the group (%); b Total number of pups born (alive or dead) 
from the whole group; c Number of pups born dead or that died within the 3 first days post partum 
(percentage); d Number of pups dead from day 4 to 31 p.p. / no. of pups alive at day 4 p.p. (percentage). 
All pups from the non-infected group that were alive on day 4 post-partum survived until the end of 
the experiment (Figure 3A), and tested negative for N. caninum DNA in the brain (Table 3). The 
survival of the pups from all infected groups was similar except for a minority of pups that survived 
longer in the crude extract group, although the survival curves were not significantly different (Log 
rank test) (Figure 3A). The number of dead neonatal mice testing positive for N. caninum DNA in the 
brain in the crude extract group was significantly lower than in the FIA group (P < 0.01, Chi-square test) 
(Table 3). All pups from each infected group died or had to be killed before the end of the experiment 
upon severe symptoms or euthanasia of the dam, except for two pups in the crude extract group.  
All pups tested positive for N. caninum DNA in the brain, and no significant difference in the 
parasite load of the infected pups was observed (Kaplan-Meier multiple comparison test) (Figure 3B). 
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Table 3. Detection of N. caninum infection in offspring mice of the different experimental groups. 
Experimental 
groups 
Nc DNA positive pups 
Mean parasite 
load (±SD)b 
Neonatal 
deaths 
Postnatal 
deaths 
Survivors Total 
Non-infected control 0/1 (0) 0/0 (0) 0/59 (0) 0/60 (0) 0 (±0) 
FIA control 8/9 (88.9) 48/48 (100) 0/0 (0) 56/57 (98.2) 1277 (±457) 
MIC3-1-R in FIA 4/7 (57.1) 25/25 (100) 0/0 (0) 29/32 (90.6) 1262 (±409) 
Crude extract in FIA 1/7 (14.3) 25/25 (100) 2/2 (100) 28/34 (82.4) 1276 (±192) 
Figure 3. Effects of vaccination in offspring. (A) Kaplan-Meier survival curves of the 
pups; n indicates the overall number of pups per group; * indicates a statistically significant 
difference compared to the FIA group (P < 0.01). (B) Cerebral parasite burden assessed by 
quantitative real-time PCR in the pups. No significant difference between the infected 
groups was observed. The y-axis represents the number of parasites detected in 20 ng of 
DNA extracted from brain tissue. 
 
2.4. Humoral Immune Response 
Antibody-reactivity against crude N. caninum extract was assessed by ELISA. Similar patterns were 
observed in the pregnant (Figure 4A) and in the non-pregnant mice (Figure 4B). In the pre-immune 
sera, as well as in the pre-infection and post-infection sera of the non-infected group, specific IgG1 and 
IgG2a levels were close to zero. In the FIA group, both IgG1 and IgG2a levels remained low after 
vaccination and were only elevated after challenge infection. After vaccination with recNcMIC3-1-R 
and crude N. caninum lysate, elevated levels of specific IgG1 and IgG2a were observed. These levels 
were all significantly higher than the respective levels in the FIA group (P < 0.001, Mann-Whitney  
U-test). After infection, both IgG1 and IgG2a levels were increased in each vaccinated groups, and 
IgG1 levels in the MIC3-1-R and crude extract group were significantly higher than in the FIA group 
(P < 0.001, Mann-Whitney U-test), while IgG2a levels reached a similar level in each group. The ratio 
IgG1/IgG2a in the post-infection sera was significantly higher in the MIC3-1-R group and in the Crude 
extract group compared to the FIA group (P < 0.01 and P < 0.001 respectively, Mann-Whitney U-test). 
The ratios were similar in the pregnant (Figure 4C) and in the non-pregnant mice (Figure 4D).  
The ratio IgG1/IgG2a in the MIC3-1-R group was below 1 in the pregnant mice and over 1 in the  
non-pregnant mice, but the difference was not significant. 
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Figure 4. Humoral immune responses measured by ELISA employing mice sera taken 
after vaccination, 7 days after mating prior to challenge infection (BI) and after challenge, 
at time of euthanasia (PI). (A) and (B) shows IgG1 and IgG2a antibody responses against 
N. caninum crude extract for pregnant and non-pregnant mice respectively. Values are 
given as OD405nm ± SD. (C) and (D): ratios of IgG1/IgG2a post-infection for pregnant 
and non-pregnant mice respectively.  Differences in antibody response were statistically 
significant: * P < 0.01, ** P < 0.001  
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2.5. Cytokine Responses 
IFN-γ, IL-4, IL-10 and IL-12(p70) levels in pre-immune, pre-infection and post-infection sera were 
measured in pools from each experimental group. Low levels of cytokines were detected in all  
pre-immune sera (data not shown), as well as in all sera from the non-infected group.  
In the FIA group, all cytokine levels were low in the pre-infection sera. IFN-γ level was increased 
up to 10 fold in the post infection sera of the pregnant and non-pregnant mice and IL-12 was slightly 
increased in the non-pregnant mice (Figure 5A,B).  
In the MIC3-1-R group, all cytokine levels in the pre-infection sera were elevated compared to  
non-infected and FIA immunized mice. While they were increased after challenge infection in the 
pregnant mice, they were all reduced in the non-pregnant ones. Post-infection IL-4, as well as IL-10 
and IL-12 levels were much higher than in the FIA group, while IFN-γ was only slightly higher 
(Figure 5A,B). 
Mice vaccinated with the crude tachyzoite lysate showed low levels of cytokines after vaccination 
and increased levels of all cytokines after challenge infection. The relative elevation of the cytokines 
post-infection was similar to that seen with the MIC3-1-R group.  
However, the post-infection IFN-γ/IL-4 ratio of all vaccinated group was equal or higher than 1 in 
both the pregnant and non-pregnant mice (Figure 5C). Moreover, this ratio was higher in the FIA 
group than in the MIC3-1-R and crude extract groups. 
2.6. Discussion of Results 
An efficient vaccine against bovine neosporosis has to prevent both horizontal and vertical 
transmission. Thus, studies in the animal model should focus on the outcomes of protection in both 
pregnant and non-pregnant animals. Among the vast number of investigations conducted in the mouse 
model, only few reported on protection against vertical transmission (reviewed in [15]). Indeed, as we 
previously showed, the same recombinant chimeric vaccine (recNcMIC3-1-R), which was protective 
in the non-pregnant mouse model [24] did not prevent the vertical transmission or the cerebral infection 
in pregnant dams [25]. The different outcomes of protection were associated with different cytokine 
profiles seen in pregnant and non-pregnant mice. A mixed Th1/Th2-type immune response was 
associated with protection in the non-pregnant mice while the lack of protection in the pregnant mice 
was associated with a Th2-type biased immune response [25]. As previously demonstrated, the choice 
of adjuvant is crucial to obtain the type of immune response sought [27,28]. In this study, we aimed to 
counterbalance the humoral immune response occurring during pregnancy by stimulating the cellular 
immune response with a Th-1 stimulator, namely FIA. Besides recNcMIC3-1-R, we included a crude 
antigen extract group due to its known partial efficacy against vertical transmission in mice [25,29] and 
cattle [13,30].  
The vaccine composed of recNcMIC3-1-R induced a Th1-type biased immune response characterised 
by high IgG2a levels and an IgG1/IgG2a ratio close to 1 in both the pregnant and non-pregnant mice. 
High IFN-γ levels were observed in the post-infection sera. However, the IFN-γ/IL-4 ratio was higher 
in the non-pregnant mice than in the pregnant mice. Unfortunately, this vaccine formulation did not 
result in a balanced Th1/Th2 response, but in a strong Th-1-type immune response. This did not 
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increase the protection against vertical transmission or cerebral infection in the pregnant mice and also 
decreased the protection against cerebral infection in the non-pregnant mice. 
Interestingly, even if the protection against vertical transmission was lost when employing FIA as 
adjuvant, the protection achieved in the mice vaccinated with the crude extract group was still better 
than in the MIC3-1-R group. This response was associated with a mixed Th1-Th2-type immune 
response. The reduction of protection in this group compared to the formulation in saponin adjuvant 
may be explained by the lower IFN-γ expression, which appeared to be crucial for the control of the 
parasite replication in vitro [30] and in the mouse model [31]. 
Figure 5. Cytokines analysis in sera taken after vaccination, prior to challenge infection 
(BI) and after challenge at the time of euthanasia (PI). The sera of all mice per group were 
pooled and analysed in triplicates. (A) and (B) represents the concentrations of IFN-γ, IL-4, 
IL-10 and IL-12 in pg/mL measured in each group for the pregnant mice and non-pregnant 
mice respectively. Values below the detection limit were set to 1 and the arbitrary value 
recommended by the kit manufacturer–1 was subtracted from measurements. Error bars 
represent the standard deviation of the triplicates. (C) Ratios of IFN-γ/IL-4 after challenge 
infection. 
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The need of the appropriate Th1/Th2 balance for protection was already demonstrated in previous 
studies [32–34]. This is important considering that a Th2-type biased response was mainly associated 
with the vertical transmission [35,36] and exacerbation of the disease [37,38]. Indeed, it was recently 
demonstrated that N. caninum tachyzoites may infect dendritic cells and disseminate intracellularly 
across the placenta and the blood-brain barrier, thus, avoiding direct contact with serum antibodies [39]. 
On the other hand, a strong Th1-type immune response appeared to cause fetal death in cattle [40], and 
be detrimental in the mouse model [41–44]. Probably other important, but still under recognized, 
factors are also necessary for protection against neosporosis. Thus, new vaccination strategies should 
focus on wider immunological aspects, alternative ways of vaccine formulations and delivery. Indeed, 
Debache et al. [45] showed different outcomes of protection between intraperitoneal and intra-nasal 
vaccinations. Recently, Debache and Hemphill [46] also demonstrated high level protection against 
experimental challenge in mice by intra-cisternal vaccination. Despite the fact that the vaccine elicited 
high IgG2a and IFN-γ expression, which could be detrimental to the fetus, the outcome of the immune 
response may be different due to the immunomodulation that occurs during pregnancy. 
3. Experimental Section  
Unless otherwise stated, all cell culture reagents were supplied by Invitrogen (Paisly, UK) and 
chemicals were purchased from Sigma (St. Louis, MO, USA). 
3.1. Culture and Purification of Parasites 
Neospora caninum tachyzoites of the Nc-1 isolate [47] were maintained by serial passages in Vero 
cells using standard procedures [24]. Tachyzoites were harvested by repeatedly passaging infected cells 
through a 25 G-needle, and liberated parasites were purified on Sephadex G25 PD-10 columns (GE 
Healthcare, Buckinghamshire, England) [48]. Parasites were counted in a Neubauer chamber using trypan 
blue stain exclusion. For challenge infections, parasite numbers were adjusted to 2 × 107/mL in RPMI 
1640 medium and tachyzoites were used immediately for infection experiments (100 µL/mouse). 
3.2. Preparation of N. caninum Crude Protein Extract 
N. caninum tachyzoites were purified as described in the previous section and adjusted to  
1 × 108 parasites/mL in sterile PBS. They were then disrupted by performing 4 freeze/thaw cycles 
using a dry-ice/methanol bath and a 37 °C water bath followed by sonication for 5 × 1 min at 57 W 
(Branson Sonifier cell disruptor, Skan AG, Allschwill, Switzerland). The parasites were observed 
microscopically to ensure that complete disruption had occurred, and the protein concentration was 
measured using the Protein Assay Dye Reagent Concentrate (Bio-Rad, Hercules, CA, USA) and 
acetylated BSA as a standard. Just prior to vaccination, the lysate was vortexed and sonicated until a 
homogenous suspension was obtained. 
3.3. Preparation of recNcMIC3-1-R 
The recombinant chimeric protein recNcMIC3-1-R was obtained as described in [24]. Briefly,  
in silico predicted putative immunogenic epitopes of NcMIC1, NcMIC3 and NcROP2 were amplified 
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from N. caninum cDNA and assembled as a single gene. RecNcMIC3-1-R was expressed in One Shot® 
BL21 (DE3) Chemically Competent E. coli (Invitrogen) and purified by Ni2+-chelate chromatography 
under denaturing conditions. After dialysis against 1 g/L ammonium bicarbonate the protein was dried 
in Speedvac and resuspended in PBS. The protein concentration was measured using the Protein Assay 
Dye Reagent Concentrate (Bio-Rad, Hercules, CA, USA) and acetylated BSA as a standard. 
3.4. Vaccination Trial, Clinical Monitoring and Sample Collection 
Six weeks old BALB/c mice were purchased from Charles River Laboratories (Sulzfeld, Germany) 
and maintained under conventional day/night cycle housing conditions as required by the animal 
welfare legislation of the Swiss Veterinary Office. They were used for experimentation after two 
weeks of acclimatization. Females were randomly allocated into four groups of twenty animals each 
and one group of 19 mice. Each group was vaccinated three times by intraperitoneal (i.p.) injection at  
2 weeks interval as follows: group 1 (non-infected) was injected with 100 μL PBS; group 2 (FIA) was 
injected with 100 μL Freund’s incomplete adjuvant (adjuvant control); group 3 (MIC3-1-R) was 
injected with 10 μg recNcMIC3-1-R emulsified in FIA; group 4 (crude extract) was vaccinated with 10 μg 
N. caninum lysate (equivalent to approximately 1 × 106 parasites). Just prior to use, freshly purified 
recNcMIC3-1-R, as well as the crude protein extract were emulsified at the appropriate concentrations 
in Freund’s incomplete adjuvant (100 μL/injection). Two weeks after the third immunization, 
synchronization of oestrus by the Whitten effect [49], followed by mating for three nights was 
performed. Seven days after mating (day 7–9 of pregnancy), all mice from groups 2–4 were challenged 
i.p. with 2 × 106 freshly purified Nc-1 tachyzoites in 100 μL RPMI 1640 medium. The mice from 
group 1 received 100 μL RPMI 1640 medium. The pregnant mice were then housed separately to rear 
their pups, and all animals were checked for clinical signs on a daily basis until day 43 post challenge. 
Data on the fertility rate (percentage of pregnant mice/group), litter size, neonatal mortality (pups born 
dead or that died within the three first days post-partum) and postnatal mortality (pups dead between 
day 4 and 31 post-partum) were collected. Dams’ weights were monitored by daily measurement from 
day 2 before challenge until the end of the experiment, and pups were weighed from day 14 post-partum 
onward. Mice exhibiting clinical signs of neosporosis (ruffled coat, apathy, neurological and walking 
disorders), were euthanized at the onset of these signs. On day 43 post challenge, all surviving dams 
and pups were sacrificed by CO2 euthanasia. Upon euthanasia, blood was drawn by cardiac puncture 
and sera were frozen at −80 °C. Brains were collected using individual sterile instruments and were 
immediately frozen at −20 °C.  
3.5. Cerebral Parasite Burden  
Neospora-specific quantitative real-time PCR to determine the number of parasites present in the 
cerebral tissue was performed as described by Müller et al. [50]. DNA extraction from brain tissue was 
performed as described [22], and DNA concentrations were adjusted to 20 ng/μL with sterile  
DNase-free water. Quantitative real-time PCR was performed using the Light Cycler™ Instrument 
(Roche Diagnostic, Basel, Switzerland). The parasite counts were calculated by interpolation from a 
standard curve with DNA equivalents from 1000, 100 and 10 parasites included in each run [25]. 
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3.6. Serology 
Individual sera taken at three distinct time points in the dams (pre-immune, post-immunization prior 
to infection (day 9 after the last immunization boost), and post-infection (at the time of euthanasia) were 
analyzed for N. caninum specific IgG1 and IgG2a by ELISA coated with N. caninum lysate prepared as 
described in section 2.2. The ELISAs were performed with a 1:100 dilution of the sera [25]. Serum from 
a mouse experimentally infected with Nc-1 that had reacted positively against N. caninum lysate in 
ELISA and serum from a non-infected mouse were used as positive and negative control, respectively. 
3.7. Serum Cytokine Levels  
Serum levels of IFN-γ, IL-4, IL-10 and IL-12(p70) were measured by means of multiplex bead 
immunoassay using the MILLIPLEX®MAP Mouse Cytokine/Chemokine kit (Millipore Corp. Billerica, 
MA, USA). Undiluted post-immunization and post-infection sera were pooled per group and analyzed in 
triplicate according to the manufacturer’s protocol. Microtitre filter plates were run on Luminex instruments 
(Bio-Plex™ 200 system, Bio-Rad), and cytokine concentrations were calculated with the Bio-Plex 
Manager software [25]. When cytokine concentration was below the detection limit, an arbitrary value 
corresponding to the detection limit of undiluted samples (provided by the kit manufacturer) was used 
for analysis. Arbitrary values corresponded to: 1 pg/mL for IFN-γ; 1 pg/mL for IL-4; 1.5 pg/mL for IL-10; 
6 pg/mL for IL-12. 
3.8. Statistical Analysis 
Dam survival and pup mortality were analyzed according to Kaplan-Meier, and the survival curves 
between groups were compared with the logrank test followed by regression coefficient analysis. Litter 
size, neonatal mortality, weight, cerebral parasite burden, as well as serological data were compared 
using Kruskal-Wallis one-way ANOVA followed by the Kruskal-Wallis multiple comparison Z-value 
test. The P-value between two significantly different groups was calculated by Mann-Whitney U test. 
The fertility rates, proportion of animals with clinical signs, and data on N. caninum DNA positive 
animals were organized in a contingency table and compared by a Chi-square test. 
4. Conclusions  
In summary, the use of FIA combined with the recombinant antigen recNcMIC3-1-R for the 
vaccination of experimentally infected mice was not protective against vertical transmission or against 
cerebral infection in pregnant and non-pregnant mice. Although the immune responses observed were 
different from those obtained with the vaccines formulated in saponin adjuvant, the shift toward a  
Th-1-type immune response may have been too strong, and the sensitive Th1/Th2 balance needed was 
not reached. This study demonstrates once again the difficulty to achieve protection against 
experimental neosporosis during pregnancy, either through a Th1- or a Th2-type immune response. 
Further recombinant vaccine development should focus on the finding of the appropriate Th1/Th2 
balance and other aspects of the immune response that were not or poorly investigated so far. The use 
of expression systems that allow to fuse antigens of interest to a suitable Toll-like receptor ligand, as 
described e.g., by Basto et al. [51] could provide the means of modulating the immune response in 
order to limit the consequences of N. caninum infection. 
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